<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>&lt;YOUR NAME HERE&gt; — HTBAA Fall 2026 :: tasnim-naseer-tahir</title><link>https://pages.htgaa.org/2026b/tasnim-naseer-tahir/index.html</link><description>About me Contact info Homework, Labs, and Projects See the nav bar on the left to look through my work for How To Biomanufacture Almost Anything (Fall 2026)!</description><generator>Hugo</generator><language>en</language><atom:link href="https://pages.htgaa.org/2026b/tasnim-naseer-tahir/index.xml" rel="self" type="application/rss+xml"/><item><title>Week 1 HW: Final Project Ideas</title><link>https://pages.htgaa.org/2026b/tasnim-naseer-tahir/week-01-hw-project-ideas/index.html</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://pages.htgaa.org/2026b/tasnim-naseer-tahir/week-01-hw-project-ideas/index.html</guid><description>Recombinant Wound-Healing Growth Factor via E. coli&#10;(1) What I want to biomanufacture, and why I want to biomanufacture recombinant human Epidermal Growth Factor (rhEGF), a small (~6.2 kDa, 53-amino-acid) signaling protein that stimulates keratinocyte and fibroblast proliferation and accelerates re-epithelialization of skin wounds. The target output is purified, biologically active rhEGF formulated into a topical cream/gel. My motivation is utilitarian and personal at once: chronic non-healing wounds (especially diabetic foot ulcers) are a major driver of lower-limb amputation worldwide, and topical growth-factor therapy is one of the few treatments shown to meaningfully speed healing. Existing approved products (e.g., rhEGF and rhPDGF-BB gels) are expensive and often unavailable in lower-resource settings. A low-cost, microbially-produced version — something that could plausibly be made with benchtop fermentation and automation rather than a large pharma facility — is interesting to me because it connects a real clinical need to a manufacturing process that is small enough to imagine building myself. It’s for patients with chronic wounds and for clinics that can’t afford imported biologics.</description></item><item><title>Final Project</title><link>https://pages.htgaa.org/2026b/tasnim-naseer-tahir/final-project/index.html</link><pubDate>Mon, 01 Jan 0001 00:00:00 +0000</pubDate><guid>https://pages.htgaa.org/2026b/tasnim-naseer-tahir/final-project/index.html</guid><description/></item></channel></rss>